The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year forecast period. Key therapies expected to fuel growth are the recently approved CAR T-cell therapies Yescarta (Gilead / Kite), Kymriah (Novartis), and Tecartus (Gilead / Kite), as well as novel, targeted agents Polivy (Roche) and Monjuvi (MorphoSys / Incyte). In addition, combinations incorporating the BTK inhibitors Imbruvica (Janssen) and Calquence (Acerta / AstraZeneca), the Bcl-2 inhibitor Venclexta / Venclyxto (AbbVie / Roche), and anti-CD20 monoclonal antibodies will enter the market, which will result in a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of the novel emerging therapies (bispecific antibody glofitamab (Roche), anti-CD19 ADC loncastuximab tesirine (ADC Therapeutics), anti-CD30 ADC Adcetris (Takeda / Seattle Genetics), and selective inhibitor of nuclear export Xpovio (Karyopharm) will further fragment the R/R DLBCL patient setting and create intense competition. Offsetting this market growth will be the biosimilar erosion expected for rituximab IV and SC, as well as the generic erosion of Celgene’s Revlimid and Janssen's Imbruvica. Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in underserved patient segments.

Questions Answered:

  • Which emerging therapies are the most promising in NHL, and what patient populations will they target? What will be their impact on the NHL market?
  • How will market share for rituximab change over the ten-year forecast period as a result of biosimilar entry? Will Roche / Genentech’s Gazyva / Gazyvaro and Rituxan Hycela / MabThera SC be able to minimize the impact of biosimilar erosion of branded rituximab?
  • The NHL therapy market will experience robust growth through 2029. What factors are driving growth in the NHL market? Which drug class will dominate the treatment of NHL? What new classes of agents will emerge over the ten-year forecast period, and what will be their market impact?

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.

Epidemiology: Diagnosed incidence of follicular lymphoma (FL) (including transformed FL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL).

Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL / SLL, DLBCL, and MCL.

Emerging therapies: Phase I/II: 19 drugs; Phase III / PR: 9 drugs.

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Arman Esfandiari, PhD; Sorcha Cassidy M.Res., Ph.D; Vandana, M.Pharm

Dr Arman Esfandiari, is an Analyst at Decision Resources Group’s Oncology and Biosimilars team. He has a longstanding interest in cancer therapeutics and holds a PhD in Cancer Biology from Newcastle University. Dr Esfandiari’s time as a Postdoctoral Research Fellow, at the Northern Institute for Cancer Research (NICR), and at University College London (UCL), was spent focusing on research and development of small molecule inhibitors, DNA damaging agents, and antibody-drug-conjugates. His roles at Decision Resources Group entail client service, extensive market research, and business insights generation pertaining the landscape of cancer therapeutics.

Sorcha Cassidy M.Res., Ph.D., is an Associate Director in the Oncology team at Decision Resources Group.  Dr. Cassidy manages a team of analysts who conduct extensive primary and secondary market research on several Oncology indications across the major pharmaceutical markets. She also provides sales and client support across all oncology products. She has in-depth expertise in competitive intelligence, secondary and primary market research, and delivering strategic insights that address key client business questions. Dr. Cassidy holds an M.Res and Ph.D in Immunology from Imperial College London where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIR) on natural killer (NK) cells in various diseases and published several peer-reviewed papers. Prior to joining the company, Dr. Cassidy previously worked as a Market Research Manager in Janssen UK and has extensive experience working across multiple Oncology indications at GlobalData and FirstWord Pharma.

Vandana is a Research Associate in the oncology team at Decision Resources Group. Her current work is focused on performing market research in several oncology indications across the major pharmaceutical markets.

Prior to joining DRG, she worked as a Business Analyst (Digital marketing) at Iquanti, Bangalore. She has also previously worked as Analyst in WNS, Noida, India. She has worked on multiple client projects involving competitive intelligence, forecasting, pipeline analysis, keywords research and product/company profiling. She has earned her Master's in Pharmacology from DIPSAR, New Delhi, India.

Related Reports

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

In this report, comissioned by Janssen in October, 2020, we estimate the following mantle cell lymphoma (MCL) patient populations for the years 2020-2030: Diagn...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Geographic Focus: China - China In-Depth | China

Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate...

View Details